HOOKVAC

Developing and testing a novel, low-cost, effective HOOKworm VACcine to control human hookworm infection in endemic countries

Objective

HOOKVAC will address four main objectives:
1. Establish safety and immunogenicity of the vaccine candidate in an endemic population;
2. Improve the manufacturing process;
3. Provide clinical proof of concept; and
4. Improve accessibility of the vaccine in endemic areas.


Description

HOOKVAC studies a candidate vaccine against hookworm infection, which ranks number one in terms of years lost from disability from a neglected infectious disease. It addresses four main objectives: 1. Establish safety and immunogenicity of the vaccine candidate in an endemic population; 2. Improve the manufacturing process; 3. Provide clinical proof of concept; and 4. Improve accessibility of the vaccine in endemic areas (sub-Saharan Africa, Southeast Asia and Latin America). HOOKVAC is developing the first and only vaccine for human hookworm infection. A bivalent, low-cost vaccine candidate is being clinically tested for the first time in an African disease endemic population. The study is being conducted in Gabon.


AIGHD Research Lead

Dr Remko van Leeuwen


Partners

AMC

Albert B. Sabin Vaccine Institute (USA)

Eberhard Karls Universitaet Tuebingen (Germany)

Centre de Recherches Medicales de Lamberéné (Gabon)

Q-Biologicals (Belgium)

Pharmidex Pharmaceutical Services (United Kingdom)

Academisch Ziekenhuis Leiden – Leids Universitair Medisch Centrum (Netherlands)

Baylor College of Medicine (USA)

George Washington University (USA)


Funders

European Union’s Seventh Framework Programme


Countries

Netherlands
Germany
Belgium
Gabon
United Kingdom
United States